Profile Response Detail

Molecular Profile Unknown unknown
Therapy Bevacizumab + Cyclophosphamide + Docetaxel + Epirubicin + Fluorouracil
Indication/Tumor Type Her2-receptor negative breast cancer
Response Type sensitive
Create By spatterson
Update By spatt

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Her2-receptor negative breast cancer sensitive Bevacizumab + Cyclophosphamide + Docetaxel + Epirubicin + Fluorouracil Phase III Actionable In a Phase III trial, treatment with the combination of Avastin (bevacizumab) and Taxotere (docetaxel), Adrucil (fluorouracil), Ellence (epirubicin), and Cytoxan (cyclophosphamide) (D-FEC) resulted in improved efficacy over D-FEC alone in ERBB2 (HER2)-negative breast cancer patients, with pathological complete response in breast and lymph nodes in 22% (87/388) of patients (PMID: 25975632). 25975632
PubMed Id Reference Title Details
(25975632) Efficacy of neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin, and cyclophosphamide, for women with HER2-negative early breast cancer (ARTemis): an open-label, randomised, phase 3 trial. Full reference...